NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... [Yahoo! Finance]
NRX Pharmaceuticals, Inc. (NRXP)
Company Research
Source: Yahoo! Finance
Loss from Operations: $4 million for Q3 2025, compared to $3 million in Q3 2024. Research and Development Expenses: Increased by $800,000 to support FDA initiatives for NRX-100 and NRX-101. General and Administrative Expenses: Increased by $400,000, including efforts related to clinic acquisitions for HOPE. Cash and Cash Equivalents: Approximately $7.1 million as of September 30, 2025, with an additional $3.1 million received in early October, totaling $10.3 million. Clinic Expansion: Anticipated growth from two clinics to six or more by year-end. Future Revenue Growth: Expected from additional acquisitions and organic growth of clinics. Warning! GuruFocus has detected 3 Warning Signs with NRXP. Is NRXP fairly valued? Test your thesis with our free DCF calculator. Release Date: November 17, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points NRX Pharmaceuticals Inc ( NASDAQ:NRXP ) has made tran
Show less
Read more
Impact Snapshot
Event Time:
NRXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXP alerts
High impacting NRX Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NRXP
News
- NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.MarketBeat
- NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic StimulationGlobeNewswire
- NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date [Yahoo! Finance]Yahoo! Finance
- NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript [Seeking Alpha]Seeking Alpha
- NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.MarketBeat
NRXP
Earnings
- 11/14/25 - Miss
NRXP
Sec Filings
- 11/26/25 - Form 8-K
- 11/21/25 - Form 8-K/A
- 11/14/25 - Form 10-Q
- NRXP's page on the SEC website